Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Glucagon‐like peptide 1 (GLP‐1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes. These medications, leveraging the effects of the insulin‐regulating hormone GLP‐1 via actions on peripheral and central nervous system targets, have raised hopes with their bariatric surgery‐rivaling results. However, questions remain about their long‐term safety and efficacy. Drawing from our expertise in obesity medicine and psychiatry, we reflect upon our experiences with the clinical use of these medications and delve into the nuanced challenges and risks they pose, particularly for those prone to disordered eating or those diagnosed with rare genetic diseases of obesity. We contend that effectively managing weight loss within this “danger zone” necessitates (1) proactive screening and continuous monitoring for disordered eating, (2) vigilant monitoring for appetite‐related maladaptive responses, including food aversion and dehydration, and (3) ongoing assessment for broader health impacts. A multifaceted, interdisciplinary approach that melds medical, psychological, dietary, and behavioral strategies is crucial to delivering tailored and thorough care to each patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“6,7 Newer agents like semaglutide and tirze-patide are showing even more remarkable results — up to 15% 8 and over 20% of total bodyweight, 9 respectively.”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
The assessment of binge eating severity among obese persons
Gormally, J., Black, S., Daston, S., & Rardin, D. (1982) · Addictive Behaviors · doi:10.1016/0306-4603(82)90024-7 · Cited by 2,129 · cited 2×
“All patients should be screened for disordered eating behaviors before starting GLP-1 agonists (e.g., via the SCOFF 26 questionnaire for abbreviated five-question screening, the Eating Disorder Examination Questionnaire 27 for a more comprehensive evaluation, or the Binge Eating Scale, 28 which assesses cognitive, beh…”
MethodAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Joint international consensus statement for ending stigma of obesity
Rubino, F., Puhl, R. M., Cummings, D. E., Eckel, R. H., Ryan, D. H., Mechanick, J. I., Nadglowski, J., Ramos Salas, X., Schauer, P. R., Twenefour, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0803-x · Cited by 1,152 · cited 1×
“We are acutely aware of the societal stigma surrounding obesity 34 and strongly oppose any form of weight-or body-related discrimination.”
BackgroundNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Obesity pandemic: causes, consequences, and solutions—but do we have the will?
Meldrum, D. R., Morris, M. A., & Gambone, J. C. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.02.104 · Cited by 457 · cited 1×
“The obesity epidemic in the United States and the worldwide obesity pandemic 18,19 represent one of human society's most visible and yet most ignored health problems.”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Medicine · doi:10.1038/s41591-023-02672-2 · Cited by 248
Cited by
Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations
Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024) · International Journal of Eating Disorders · doi:10.1002/eat.24109 · Cited by 81
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416985 · Cited by 40
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
“Given these alterations in eating patterns, concerns have been raised that GLP-1 RAs may exacerbate pre-existing eating disorders or contribute to disordered eating behaviors in susceptible individuals [45].”
Metadata
- Authors
- Richards, J. R., & Khalsa, S. S.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2024-02-06
- Volume
- 25
- Issue
- 5
- Pages
- e13709-e13709
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W4391613972
- Cited by
- 36
- References
- 14
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss. https://app.cochat.ai/papers/10.1111/obr.13709
- The paper
- Richards, J. R., & Khalsa, S. S. (2024). Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews. https://doi.org/10.1111/obr.13709
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.